Richard Anthony R. Coulden MD, Presenter: Nothing to Disclose

Emer Sonnex, Abstract Co-Author: Nothing to Disclose

Hefin Jones FRCR, Abstract Co-Author: Nothing to Disclose

Indrajeet Das MBBCh, MRCP, Abstract Co-Author: Nothing to Disclose

Jonathan Thomas Abele MD, Abstract Co-Author: Nothing to Disclose

In patients with established non-cardiac sarcoidosis, both FDG PET/CT and cardiac MRI can be used to diagnose cardiac involvement. We will learn how and why: 1. FDG PET/CT identifies active disease and can be used in both diagnosis and management. Serial PET allows assessment of response to immunosuppressive treatment. 2. Cardiac MRI identifies myocardial edema and scar. It has proven value in diagnosis but its role in monitoring disease in response to treatment is unclear. 3. Cardiac MRI provides additional value in assessment of ventricular volumes and function and maybe a helpful surrogate in monitoring treatment response. 4. FDG PET/CT and MRI are complementary techniques.  

1. Criteria for clinical diagnosis of cardiac sarcoidosis (Japanese Ministry of Health and Welfare) 2. How to use FDG PET/CT for inflammatory cardiac imaging 3. How to use cardiac MRI for infiltrative cardiomyopathies 4. Relative roles of Cardiac MRI & FDG PET/CT in: a. the imaging diagnosis of cardiac sarcoidosis b. follow-up of disease activity and response to immunosuppressive treatment.  

http://abstract.rsna.org/uploads/2014/14016087/14016087_mqxb.pdf

Coulden, R, Sonnex, E, Jones, H, Das, I, Abele, J, F-18 FDG PET/CT and MRI In the Diagnosis and Management of Cardiac Sarcoidosis.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14016087.html